Shumpei Yokota

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

Shumpei Yokota, Tomoyuki Imagawa, Masaaki Mori et al. · The Lancet · 2008 · 797 citations

Medicine, Clinical Sciences, Pharmacotherapy +8

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Yoshikazu Nakaoka, Mitsuaki Isobe, Syuji Takei et al. · Annals of the Rheumatic Diseases · 2017 · 386 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +13

Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritis

Shumpei Yokota, Takako Miyamae, Tomoyuki Imagawa et al. · Arthritis & Rheumatism · 2005 · 372 citations

Medicine, Pediatrics, Pharmacotherapy +13

Prognostic Factors for Chronic Active Epstein‐Barr Virus Infection

Hiroshi Kimura, Tsuneo Morishima, Hirokazu Kanegane et al. · The Journal of Infectious Diseases · 2003 · 252 citations · Full text

Medicine, Hematology, Infectious Diseases +11

Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus

Utako Yokoyama, Susumu Minamisawa, Hong Quan et al. · Journal of Clinical Investigation · 2006 · 172 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +15